ΣΥΜΒΟΛΗ ΣΤΗΝ ΜΕΛΕΤΗ ΤΩΝ ΛΟΙΜΩΞΕΩΝ ΑΠΟ ΜΕΓΑΛΟΚΥΤΤΑΡΟΙΟ (CMV) ΣΤΟΥΣ ΛΗΠΤΕΣ ΝΕΦΡΙΚΩΝ ΜΟΣΧΕΥΜΑΤΩΝ. ΣΥΣΧΕΤΙΣΗ ΜΕ HLA ΑΝΤΙΓΟΝΑ

THE RATE OF ANTIBODIES TO CMV VIRUS, THE CLINICAL FEATURES OF THE DISEASE, ITS INTERFERENCE WITH GRAFT REJECTION AS WELL AS ITS CORRELATION TO HLA, WERE STUDIED IN 47 KIDNEY GRAFT RECIPIENTS. RESULTS CAN BE SUMMARISED AS FOLLOWS: A) ANTIBODIES TO CMV VIRUS WERE FOUND IN 58.9% OF THE RECIPIENTS. IN A CONTROL POPULATION STUDY ANTIBODIES TO CMV WERE FOUND IN 55.46%. B) RECIPIENTS WHO RECEIVED A GRAFT FROM SERONEGATIVE DONORS, DID NOT PRODUCE ANY CMV ANTIBODIES. C) 44.6% OFTHE RECIPIENTS WHO RECEIVED KIDNEYS FROM SEROPOSITIVE DONORS, PRODUCED CMV ANTIBODIES WHILE THE REMAINING 55.6% CONTINUED TO BE SERONEGATIVE. D) THERE ARE INDICATIONS STRONGLY SUGGESTING THAT HLA-A1 IS POSITIVELY CORRELATED WITH INCREASED CMV INFECTION IN THE RECIPIENTS TESTED. HLA-A1 RECIPIENTS SHOWED HIGHER PERCENTAGE OF CMV SEROPOSITIVE REACTIONS. E) HLA-A2 BW35 HAPLOTYPE SEEMS TO BE NEGATIVELY RELATED TO CMV INFECTION. RECIPIENTS BEANING A2 BW35 HAPLOTYPE WERE FOUND TO HAVE THE LOWEST PERCENTAGE OF CMV IN STATISTICAL SIGNIFICANT LEVEL. F) AVAILABLE THERAPEUTIC MANAGEMENTS ARE NOT PROVED SATISFACTORY FOR TREATMENT OF CMVDISEASE.

Grantor dc:publisher

National and Kapodistrian University of Athens

Year dc:date

1985

Authors dc:creator

• Drakopoulos, Spiros
• Δρακόπουλος, Σπύρος

• CMV ΛΟΙΜΩΞΕΙΣ
• ΑΝΤΙΓΟΝΑ ΣΥΣΤΗΜΑΤΟΣ HLA
• Νεφρική μεταμόσχευση
• Ιατρική και Επιστήμες Υγείας
• Κλινική Ιατρική
• Medical and Health Sciences
• Clinical Medicine

Language dc:language

gre

Identifier

10.12681/eadd/0319

OAI identifier oai:identifier

oai:10442/0319